Introduction

Exploring the use of bi-specific antibodies in relapsed/refractory multiple myeloma, including recent FDA approvals and their impact on heavily pre-treated patients. Emphasizing the importance of off-the-shelf agents targeting specific markers and the necessity of real-world data for informed treatment decisions in the changing landscape of multiple myeloma therapy.